Considering the upregulated PD-1 expression in tumor-infiltrating CD4+ and CD8+ T-cells of Nhe1 KO mice, we tested whether these mice were more sensitive to TMZ plus anti-PD-1 combinatorial therapy. The gene discussed is SLC9A1; the disease is neoplasm.